Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

4.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
4.0K
Epigenetic Regulation01:46

Epigenetic Regulation

34.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Distinctive features of the tumor and immune microenvironment in glioblastoma.

NPJ precision oncology·2026
Same author

Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma.

Oncoimmunology·2026
Same author

Response to "Updated local safety standards for invasive procedures: Guidance or suggestions?" letter.

Journal of the Intensive Care Society·2025
Same author

Correction: T cell-derived small extracellular vesicles in cancer-immune interactions.

Cancer immunology, immunotherapy : CII·2025
Same author

T cell-derived small extracellular vesicles in cancer-immune interactions.

Cancer immunology, immunotherapy : CII·2025

Related Experiment Video

Updated: Feb 28, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Epigenetic modulation in cancer immunotherapy.

Stuart J Gallagher1, Elena Shklovskaya1, Peter Hersey1

  • 1Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Camperdown, NSW, Australia; Melanoma Institute Australia, Crow's Nest 2065, Sydney, Australia.

Current Opinion in Pharmacology
|June 14, 2017
PubMed
Summary

Epigenetic modifications can enhance cancer immunotherapy by overcoming resistance to immune checkpoint inhibitors like CTLA4 and PD1. Targeting epigenetic pathways offers a promising strategy to improve patient responses and combat tumor evasion.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.9K

Related Experiment Videos

Last Updated: Feb 28, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.9K

Area of Science:

  • Immunology
  • Oncology
  • Epigenetics

Background:

  • Immune checkpoint inhibitors targeting CTLA4 and PD1 have shown success in cancer immunotherapy.
  • Many patients do not respond to these therapies, and acquired tumor resistance is a significant challenge.
  • Cancer cells employ immune avoidance and escape mechanisms that limit immunotherapy efficacy.

Purpose of the Study:

  • To review recent findings on the role of epigenetics in improving cancer immunotherapy.
  • To explore how epigenetic targeting can reverse immune evasion and modulate immune cell function.
  • To focus on epigenetic modifiers of histone acetylation, methylation, and DNA methylation in conjunction with CTLA4 and PD1 inhibitors.

Main Methods:

  • Literature review of recent scientific findings and research.
  • Analysis of epigenetic mechanisms including histone acetylation, methylation, and DNA methylation.
  • Examination of the interplay between epigenetic modifiers and immune checkpoints (CTLA4, PD1).

Main Results:

  • Epigenetic targeting can reverse immune avoidance and escape mechanisms in cancer cells.
  • Modulating epigenetic pathways can enhance immune cell differentiation and function.
  • Specific epigenetic modifiers show potential in combination with CTLA4 and PD1 inhibitors to improve therapeutic outcomes.

Conclusions:

  • Epigenetic strategies hold significant promise for enhancing the efficacy of current cancer immunotherapies.
  • Targeting epigenetic modifications may overcome resistance and improve responses to immune checkpoint inhibitors.
  • Further research into epigenetic modifiers offers a pathway to more effective cancer treatments.